Thursday, September 24, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchsemaglutideglp-1cardiovasculareuropean heart journal

European Heart Journal review probes unexplained semaglutide mechanisms

Verma, Guzik, Cosentino and colleagues survey what remains unknown about how the GLP-1 agonist produces cardiovascular benefit.

PR
By Priya Raman · Science Reporter
Sep 22 20:00 ETSource: European heart journal

The wire

  1. 01A review in European Heart Journal, published 23 September 2026, examines gaps in the understanding of semaglutide's mechanisms of action.
  2. 02Clinicians prescribing semaglutide for cardiometabolic indications have argued over how much benefit is weight-independent; the review addresses that question directly.
  3. 03It is a narrative review rather than new trial data, and the abstract text available gives no specific conclusions.

From the source

Semaglutide mechanisms of action: the missing pieces

European heart journal · 2026 Sep 23 · Verma S, Guzik TJ, Cosentino F et al.

Read at pubmed.ncbi.nlm.nih.gov
PeptiPrescribed peptides from $99/moSee all →